The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

To evaluate the effect of anastrazole on symptomatic uterine leiomyomata. This was a prospective intervention study carried out in a university department of obstetrics and gynecology. Forty-one premenopausal women eligible for hysterectomy with 45 uterine leiomyomata were enrolled and treated with...

Full description

Saved in:

Bibliographic Details
Published in:	Obstetrics and gynecology (New York. 1953) Vol. 110; no. 3; pp. 643 - 649
Main Authors:	Varelas, Fotios K., Papanicolaou, Alexis N., Vavatsi-Christaki, Norma, Makedos, Georgios A., Vlassis, Georgios D.
Format:	Journal Article
Language:	English
Published:	New York, NY by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved 01-09-2007 Elsevier Science
Subjects:	Adult Age Factors Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Endometrium - drug effects Endometrium - pathology Estradiol - blood Female Female genital diseases Gonadotropins - blood Gynecology. Andrology. Obstetrics Hematocrit Humans Leiomyomatosis - blood Leiomyomatosis - drug therapy Leiomyomatosis - pathology Medical sciences Middle Aged Nitriles - adverse effects Nitriles - therapeutic use Organ Size - drug effects Prospective Studies Severity of Illness Index Treatment Outcome Triazoles - adverse effects Triazoles - therapeutic use Tumors Uterine Neoplasms - blood Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology Uterine diseases Uterine leiomyoma Benign neoplasm Obstetrics Gynecology Female genital diseases
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To evaluate the effect of anastrazole on symptomatic uterine leiomyomata. This was a prospective intervention study carried out in a university department of obstetrics and gynecology. Forty-one premenopausal women eligible for hysterectomy with 45 uterine leiomyomata were enrolled and treated with anastrazole 1 mg daily for three cycles of 28 days each. The effect of treatment was evaluated on leiomyoma and uterine volumes, endometrial thickness, gonadotrophins, estradiol and hematocrit levels, menstrual pattern, severity of leiomyoma-related symptoms, and adverse effects. The effects of leiomyoma location, size, and age of participants on tumor volume changes were evaluated. Thirty-five women with 39 leiomyomata finished the study. Anastrazole resulted in a mean 55.7% reduction of leiomyoma volumes (163 mL to 72 mL, P<.001), a 29.9% reduction in total uterine volumes (278 mL to 195 mL, P<.001), and an 11.3% increase of the hematocrit levels (33.4% to 37.2%, P<.001) at the end of the treatment. Leiomyoma location had no significant effect on volume decrease. Leiomyoma volume decreased in women aged older than 40 years (P=.002), whereas no difference was found in women younger than 40. The size of large (greater than 50 mm) leiomyomata decreased significantly (P=.004). Less difference was observed in small (50 mm or less) leiomyomata (P=.031). No differences were detected in hormonal status. Anastrazole improved leiomyoma-related symptomatology and caused no serious adverse effects. In premenopausal women, anastrazole reduces the size of uterine leiomyomata, improves symptomatology, and is generally well tolerated. III.
ISSN:	0029-7844 1873-233X
DOI:	10.1097/01.AOG.0000279151.20878.60